Founded with a mission to revolutionize cancer and autoimmune disease treatment, Immunicom focuses on developing non-drug-based therapies. Their flagship product, Immunopheresis®, is designed to enhance patients' quality of life by avoiding the typical side effects associated with conventional treatments. The company aims to redefine the limits of immunotherapy, targeting cancer, inflammatory diseases, and autoimmune conditions through innovative, non-pharmaceutical approaches.
Notable achievements include securing significant funding from the National Cancer Institute (NCI) and the National Institutes of Health (NIH) to initiate clinical trials for their breakthrough Immunopheresis® LW-Molecular Subtractive Therapy in refractory ER+/Her2- breast cancer. This milestone underscores Immunicom's impact on advancing cancer treatment. The company is supported by a team of leading experts in oncology and immunotherapy, positioning it as a pioneering force in the medical field.
